JP2019524705A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019524705A5 JP2019524705A5 JP2019500377A JP2019500377A JP2019524705A5 JP 2019524705 A5 JP2019524705 A5 JP 2019524705A5 JP 2019500377 A JP2019500377 A JP 2019500377A JP 2019500377 A JP2019500377 A JP 2019500377A JP 2019524705 A5 JP2019524705 A5 JP 2019524705A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- benzyl
- chloro
- methoxy
- oxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 28
- 239000001257 hydrogen Substances 0.000 claims 28
- 125000005843 halogen group Chemical group 0.000 claims 26
- 150000002431 hydrogen Chemical class 0.000 claims 20
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 20
- -1 -N (CH 3) 2 Chemical group 0.000 claims 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 10
- 229910052757 nitrogen Inorganic materials 0.000 claims 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 7
- 125000003368 amide group Chemical group 0.000 claims 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 125000002950 monocyclic group Chemical group 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000004429 atom Chemical group 0.000 claims 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000004043 oxo group Chemical group O=* 0.000 claims 4
- 239000001301 oxygen Substances 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 239000011593 sulfur Substances 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000002619 bicyclic group Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 2
- GZPHSAQLYPIAIN-UHFFFAOYSA-N 3-pyridinecarbonitrile Chemical compound N#CC1=CC=CN=C1 GZPHSAQLYPIAIN-UHFFFAOYSA-N 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- GXZGAKZGEMMYNJ-JGCGQSQUSA-N (2R)-2-[[5-chloro-2-[(5-cyanopyridin-3-yl)methoxy]-4-[[3-(4-formyl-3,5-dimethylpyrazol-1-yl)-2-methylphenyl]methoxy]phenyl]methylamino]-3-hydroxy-2-methylpropanoic acid Chemical compound ClC=1C(=CC(=C(CN[C@@](C(=O)O)(CO)C)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)N1N=C(C(=C1C)C=O)C)C GXZGAKZGEMMYNJ-JGCGQSQUSA-N 0.000 claims 1
- NUSXRHUFHUAGCW-NXVGIJDASA-N (2R)-2-[[5-chloro-2-[(5-cyanopyridin-3-yl)methoxy]-4-[[3-[1-[4-[(3S)-3-hydroxypyrrolidin-1-yl]butyl]-3,5-dimethylpyrazol-4-yl]-2-methylphenyl]methoxy]phenyl]methylamino]-3-hydroxy-2-methylpropanoic acid Chemical compound ClC=1C(=CC(=C(CN[C@@](C(=O)O)(CO)C)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C=1C(=NN(C=1C)CCCCN1C[C@H](CC1)O)C)C NUSXRHUFHUAGCW-NXVGIJDASA-N 0.000 claims 1
- MWUOFFRBBLJGJC-JQMWFGOGSA-N (2R)-2-[[5-chloro-2-[(5-cyanopyridin-3-yl)methoxy]-4-[[3-[4-[[(3R)-3-hydroxypyrrolidin-1-yl]methyl]-3,5-dimethylpyrazol-1-yl]-2-methylphenyl]methoxy]phenyl]methylamino]-3-hydroxy-2-methylpropanoic acid Chemical compound ClC=1C(=CC(=C(CN[C@@](C(=O)O)(CO)C)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)N1N=C(C(=C1C)CN1C[C@@H](CC1)O)C)C MWUOFFRBBLJGJC-JQMWFGOGSA-N 0.000 claims 1
- ZXGHTQAKECUTMN-KUFVUHJUSA-N (2S)-1-[[5-chloro-2-[(5-cyanopyridin-3-yl)methoxy]-4-[[3-[1-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propyl]-2-oxopyridin-3-yl]-2-methylphenyl]methoxy]phenyl]methyl]piperidine-2-carboxylic acid Chemical compound ClC=1C(=CC(=C(CN2[C@@H](CCCC2)C(=O)O)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C=1C(N(C=CC=1)CCCN1C[C@@H](CC1)O)=O)C ZXGHTQAKECUTMN-KUFVUHJUSA-N 0.000 claims 1
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 claims 1
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- SWJOCPYUANLJCB-UUWRZZSWSA-N BrC1=CC=C2N=CC(=NC2=C1)C=1C(=C(COC2=CC(=C(CN[C@@](C(=O)O)(CO)C)C=C2Cl)OCC=2C=NC=C(C=2)C#N)C=CC=1)C Chemical compound BrC1=CC=C2N=CC(=NC2=C1)C=1C(=C(COC2=CC(=C(CN[C@@](C(=O)O)(CO)C)C=C2Cl)OCC=2C=NC=C(C=2)C#N)C=CC=1)C SWJOCPYUANLJCB-UUWRZZSWSA-N 0.000 claims 1
- FFDMQWOCFFLAMR-UHFFFAOYSA-N ClC1=CC(=C(OCC=2C=NC=C(C#N)C=2)C=C1OCC1=C(C(=CC=C1)C1=C(C(=NC=C1)OCCCN1CCCCC1)Cl)C)CNC(CO)(CO)C Chemical compound ClC1=CC(=C(OCC=2C=NC=C(C#N)C=2)C=C1OCC1=C(C(=CC=C1)C1=C(C(=NC=C1)OCCCN1CCCCC1)Cl)C)CNC(CO)(CO)C FFDMQWOCFFLAMR-UHFFFAOYSA-N 0.000 claims 1
- PIFUSVHHVLNCQH-MUUNZHRXSA-N ClC1=CC(=C(OCC=2C=NC=C(C#N)C=2)C=C1OCC1=C(C(=CC=C1)C1=NC(=CC=C1)OCCCN1C[C@@H](CC1)O)C)CO Chemical compound ClC1=CC(=C(OCC=2C=NC=C(C#N)C=2)C=C1OCC1=C(C(=CC=C1)C1=NC(=CC=C1)OCCCN1C[C@@H](CC1)O)C)CO PIFUSVHHVLNCQH-MUUNZHRXSA-N 0.000 claims 1
- POPXQHLYZQCOTH-UHFFFAOYSA-N ClC1=CC(=C(OCC=2C=NC=C(C#N)C=2)C=C1OCC1=C(C(=CC=C1)C1=NC=CC(=C1Cl)OCCCO)C)CNC(CO)(CO)C Chemical compound ClC1=CC(=C(OCC=2C=NC=C(C#N)C=2)C=C1OCC1=C(C(=CC=C1)C1=NC=CC(=C1Cl)OCCCO)C)CNC(CO)(CO)C POPXQHLYZQCOTH-UHFFFAOYSA-N 0.000 claims 1
- UVRIYWVLPXFKJP-MUUNZHRXSA-N ClC1=CC(=C(OCC=2C=NC=C(C#N)C=2)C=C1OCC1=C(C(=CC=C1)C=1C=CC2=C(N=C(O2)CCN2C[C@@H](CC2)O)C=1)C)C=O Chemical compound ClC1=CC(=C(OCC=2C=NC=C(C#N)C=2)C=C1OCC1=C(C(=CC=C1)C=1C=CC2=C(N=C(O2)CCN2C[C@@H](CC2)O)C=1)C)C=O UVRIYWVLPXFKJP-MUUNZHRXSA-N 0.000 claims 1
- PHOFLIDUQMGIEX-FIRIVFDPSA-N ClC1=CC(=C(OCC=2C=NC=C(C#N)C=2)C=C1OCC1=C(C(=CC=C1)N1N=C(C(=C1C)CN1C[C@@H](CC1)O)C)C)CN1C[C@@H](CC1)O Chemical compound ClC1=CC(=C(OCC=2C=NC=C(C#N)C=2)C=C1OCC1=C(C(=CC=C1)N1N=C(C(=C1C)CN1C[C@@H](CC1)O)C)C)CN1C[C@@H](CC1)O PHOFLIDUQMGIEX-FIRIVFDPSA-N 0.000 claims 1
- IDLUKFOTOBOHGX-UHFFFAOYSA-N ClC1=CC(=C(OCC=2C=NC=C(C#N)C=2)C=C1OCC1=NC=CC(=C1C)C1=C(C(=CC=C1)OCCCN1CCCCC1)C)CNC(CO)(CC)CO Chemical compound ClC1=CC(=C(OCC=2C=NC=C(C#N)C=2)C=C1OCC1=NC=CC(=C1C)C1=C(C(=CC=C1)OCCCN1CCCCC1)C)CNC(CO)(CC)CO IDLUKFOTOBOHGX-UHFFFAOYSA-N 0.000 claims 1
- AKKBIEZYVLKDMU-JGCGQSQUSA-N ClC1=CC(=C(OCC=2C=NC=C(C#N)C=2)C=C1OCC1=NC=CC(=C1C)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)CNC(CO)(CC)CO Chemical compound ClC1=CC(=C(OCC=2C=NC=C(C#N)C=2)C=C1OCC1=NC=CC(=C1C)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)CNC(CO)(CC)CO AKKBIEZYVLKDMU-JGCGQSQUSA-N 0.000 claims 1
- NKGHXZANVYAHOW-JGCGQSQUSA-N ClC1=CC(=C(OCC=2C=NC=C(C#N)C=2)C=C1OCC=1C=NC=C(C=1C)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)CNC(CO)(CO)C Chemical compound ClC1=CC(=C(OCC=2C=NC=C(C#N)C=2)C=C1OCC=1C=NC=C(C=1C)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)CNC(CO)(CO)C NKGHXZANVYAHOW-JGCGQSQUSA-N 0.000 claims 1
- AGPGILJKTUMUJW-KUFVUHJUSA-N ClC=1C(=CC(=C(CN2[C@@H](CCCC2)C(=O)O)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C1=NC(=CC=C1)OCCCN1C[C@@H](CC1)O)C Chemical compound ClC=1C(=CC(=C(CN2[C@@H](CCCC2)C(=O)O)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C1=NC(=CC=C1)OCCCN1C[C@@H](CC1)O)C AGPGILJKTUMUJW-KUFVUHJUSA-N 0.000 claims 1
- STDOIPYSVOFITM-XIFFEERXSA-N ClC=1C(=CC(=C(CN2[C@@H](CCCC2)C(=O)O)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C=1C=C2N=CC=NC2=CC=1)C Chemical compound ClC=1C(=CC(=C(CN2[C@@H](CCCC2)C(=O)O)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C=1C=C2N=CC=NC2=CC=1)C STDOIPYSVOFITM-XIFFEERXSA-N 0.000 claims 1
- HQVSKHZMSPNDNX-KUFVUHJUSA-N ClC=1C(=CC(=C(CN2[C@@H](CCCC2)C(=O)O)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C=1C=CC2=C(N=C(O2)CCN2C[C@@H](CC2)O)C=1)C Chemical compound ClC=1C(=CC(=C(CN2[C@@H](CCCC2)C(=O)O)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C=1C=CC2=C(N=C(O2)CCN2C[C@@H](CC2)O)C=1)C HQVSKHZMSPNDNX-KUFVUHJUSA-N 0.000 claims 1
- DNHWXFSYLWIPCL-UMSFTDKQSA-N ClC=1C(=CC(=C(CN2[C@@H](CCCC2)C(=O)O)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C=1C=NC2=CC=CC=C2C=1)C Chemical compound ClC=1C(=CC(=C(CN2[C@@H](CCCC2)C(=O)O)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C=1C=NC2=CC=CC=C2C=1)C DNHWXFSYLWIPCL-UMSFTDKQSA-N 0.000 claims 1
- QMGAYGYXJOGMMB-LHEWISCISA-N ClC=1C(=CC(=C(CN2[C@@H](CCCC2)C(=O)O)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=NC=CC(=C1C)C1=C(C(=CC=C1)OCCCN1CCCCC1)C Chemical compound ClC=1C(=CC(=C(CN2[C@@H](CCCC2)C(=O)O)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=NC=CC(=C1C)C1=C(C(=CC=C1)OCCCN1CCCCC1)C QMGAYGYXJOGMMB-LHEWISCISA-N 0.000 claims 1
- PILNQGZWWKKPKY-JJQXXVEZSA-N ClC=1C(=CC(=C(CN2[C@@H](CCCC2)C(=O)O)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=NC=CC(=C1C)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C Chemical compound ClC=1C(=CC(=C(CN2[C@@H](CCCC2)C(=O)O)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=NC=CC(=C1C)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C PILNQGZWWKKPKY-JJQXXVEZSA-N 0.000 claims 1
- YRQZWYNCWODQFS-GOJCVTOHSA-N ClC=1C(=CC(=C(CN2[C@@H](CCCC2)C(=O)O)C=1)OCC=1C=NC=C(C=1)C#N)OCC=1C=NC=C(C=1C)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C Chemical compound ClC=1C(=CC(=C(CN2[C@@H](CCCC2)C(=O)O)C=1)OCC=1C=NC=C(C=1)C#N)OCC=1C=NC=C(C=1C)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C YRQZWYNCWODQFS-GOJCVTOHSA-N 0.000 claims 1
- STDOIPYSVOFITM-MGBGTMOVSA-N ClC=1C(=CC(=C(CN2[C@H](CCCC2)C(=O)O)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C=1C=C2N=CC=NC2=CC=1)C Chemical compound ClC=1C(=CC(=C(CN2[C@H](CCCC2)C(=O)O)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C=1C=C2N=CC=NC2=CC=1)C STDOIPYSVOFITM-MGBGTMOVSA-N 0.000 claims 1
- VTJSQFMSMQMYNL-UHFFFAOYSA-N ClC=1C(=CC(=C(CNC(C(=O)O)(C)C)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(N(C=N2)CCN(C)C)C=C1)C Chemical compound ClC=1C(=CC(=C(CNC(C(=O)O)(C)C)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(N(C=N2)CCN(C)C)C=C1)C VTJSQFMSMQMYNL-UHFFFAOYSA-N 0.000 claims 1
- GDEJCNHZVLVNEC-UHFFFAOYSA-N ClC=1C(=CC(=C(CNC(C(=O)O)(C)C)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C=1C=CC2=C(N(C=N2)CCN(C)C)C=1)C Chemical compound ClC=1C(=CC(=C(CNC(C(=O)O)(C)C)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C=1C=CC2=C(N(C=N2)CCN(C)C)C=1)C GDEJCNHZVLVNEC-UHFFFAOYSA-N 0.000 claims 1
- PKLCBTBOOZBFED-JGCGQSQUSA-N ClC=1C(=CC(=C(CN[C@@H](C(=O)O)CO)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(N(C=N2)CCN(C)C)C=C1)C Chemical compound ClC=1C(=CC(=C(CN[C@@H](C(=O)O)CO)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(N(C=N2)CCN(C)C)C=C1)C PKLCBTBOOZBFED-JGCGQSQUSA-N 0.000 claims 1
- BAOXXDDWRGRVSM-SSEXGKCCSA-N ClC=1C(=CC(=C(CN[C@@H](C(=O)O)CO)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C=1C=C2N=CC=NC2=CC=1)C Chemical compound ClC=1C(=CC(=C(CN[C@@H](C(=O)O)CO)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C=1C=C2N=CC=NC2=CC=1)C BAOXXDDWRGRVSM-SSEXGKCCSA-N 0.000 claims 1
- VVCZZPCPNAQESI-JGCGQSQUSA-N ClC=1C(=CC(=C(CN[C@@H](C(=O)O)CO)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C=1C=CC2=C(N(C=N2)CCN(C)C)C=1)C Chemical compound ClC=1C(=CC(=C(CN[C@@H](C(=O)O)CO)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C=1C=CC2=C(N(C=N2)CCN(C)C)C=1)C VVCZZPCPNAQESI-JGCGQSQUSA-N 0.000 claims 1
- WOUXWMPGUCIXHU-PGUFJCEWSA-N ClC=1C(=CC(=C(CN[C@@](C(=O)O)(CO)C)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C1=CC=C2C=CC=NC2=C1)C Chemical compound ClC=1C(=CC(=C(CN[C@@](C(=O)O)(CO)C)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C1=CC=C2C=CC=NC2=C1)C WOUXWMPGUCIXHU-PGUFJCEWSA-N 0.000 claims 1
- UAOXUXMYYLVSCB-PGUFJCEWSA-N ClC=1C(=CC(=C(CN[C@@](C(=O)O)(CO)C)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C1=CC=C2C=CN=CC2=C1)C Chemical compound ClC=1C(=CC(=C(CN[C@@](C(=O)O)(CO)C)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C1=CC=C2C=CN=CC2=C1)C UAOXUXMYYLVSCB-PGUFJCEWSA-N 0.000 claims 1
- LVKKGLXHUOEDSN-PGUFJCEWSA-N ClC=1C(=CC(=C(CN[C@@](C(=O)O)(CO)C)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C1=NC2=CC=CC=C2C=C1)C Chemical compound ClC=1C(=CC(=C(CN[C@@](C(=O)O)(CO)C)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C1=NC2=CC=CC=C2C=C1)C LVKKGLXHUOEDSN-PGUFJCEWSA-N 0.000 claims 1
- KJGBSKXWCFJEDI-UUWRZZSWSA-N ClC=1C(=CC(=C(CN[C@@](C(=O)O)(CO)C)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C1=NC2=CC=CC=C2N=C1)C Chemical compound ClC=1C(=CC(=C(CN[C@@](C(=O)O)(CO)C)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C1=NC2=CC=CC=C2N=C1)C KJGBSKXWCFJEDI-UUWRZZSWSA-N 0.000 claims 1
- DMTZFFWMPMJNHX-UKZNZPTOSA-N ClC=1C(=CC(=C(CN[C@@](C(=O)O)(CO)C)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C=1C(N(C=CC=1)CCCN1C[C@@H](CC1)O)=O)C Chemical compound ClC=1C(=CC(=C(CN[C@@](C(=O)O)(CO)C)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C=1C(N(C=CC=1)CCCN1C[C@@H](CC1)O)=O)C DMTZFFWMPMJNHX-UKZNZPTOSA-N 0.000 claims 1
- WIYXHCHZPCEPMG-PGUFJCEWSA-N ClC=1C(=CC(=C(CN[C@@](C(=O)O)(CO)C)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C=1C=C2C=CC=NC2=CC=1)C Chemical compound ClC=1C(=CC(=C(CN[C@@](C(=O)O)(CO)C)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C=1C=C2C=CC=NC2=CC=1)C WIYXHCHZPCEPMG-PGUFJCEWSA-N 0.000 claims 1
- WKROVGSDEJBQCO-PGUFJCEWSA-N ClC=1C(=CC(=C(CN[C@@](C(=O)O)(CO)C)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C=1C=C2C=CN=CC2=CC=1)C Chemical compound ClC=1C(=CC(=C(CN[C@@](C(=O)O)(CO)C)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C=1C=C2C=CN=CC2=CC=1)C WKROVGSDEJBQCO-PGUFJCEWSA-N 0.000 claims 1
- ZPCKOICHPNUGPA-UUWRZZSWSA-N ClC=1C(=CC(=C(CN[C@@](C(=O)O)(CO)C)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C=1C=C2N=CC=NC2=CC=1)C Chemical compound ClC=1C(=CC(=C(CN[C@@](C(=O)O)(CO)C)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C=1C=C2N=CC=NC2=CC=1)C ZPCKOICHPNUGPA-UUWRZZSWSA-N 0.000 claims 1
- LJZYEFRTYGMVTC-GFZJOKKCSA-N ClC=1C(=CC(=C(CN[C@@](C(=O)O)(CO)C)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C=1C=CC2=C(N=C(O2)CCN2C[C@@H](CC2)O)C=1)C Chemical compound ClC=1C(=CC(=C(CN[C@@](C(=O)O)(CO)C)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C=1C=CC2=C(N=C(O2)CCN2C[C@@H](CC2)O)C=1)C LJZYEFRTYGMVTC-GFZJOKKCSA-N 0.000 claims 1
- FMYGSHUIBPFJQX-PGUFJCEWSA-N ClC=1C(=CC(=C(CN[C@@](C(=O)O)(CO)C)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C=1C=NC2=CC=CC=C2C=1)C Chemical compound ClC=1C(=CC(=C(CN[C@@](C(=O)O)(CO)C)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C=1C=NC2=CC=CC=C2C=1)C FMYGSHUIBPFJQX-PGUFJCEWSA-N 0.000 claims 1
- TXXJCNMPBOMGIY-PGUFJCEWSA-N ClC=1C(=CC(=C(CN[C@@](C(=O)O)(CO)C)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C=1N=CC2=CC=CC=C2C=1)C Chemical compound ClC=1C(=CC(=C(CN[C@@](C(=O)O)(CO)C)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C=1N=CC2=CC=CC=C2C=1)C TXXJCNMPBOMGIY-PGUFJCEWSA-N 0.000 claims 1
- QWMJODMJKVKJPA-CPBHLAHYSA-N ClC=1C(=CC(=C(CN[C@H](C(=O)O)CO)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C=1C(N(C=CC=1)CCCN1C[C@@H](CC1)O)=O)C Chemical compound ClC=1C(=CC(=C(CN[C@H](C(=O)O)CO)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C=1C(N(C=CC=1)CCCN1C[C@@H](CC1)O)=O)C QWMJODMJKVKJPA-CPBHLAHYSA-N 0.000 claims 1
- DMTZFFWMPMJNHX-KLFBTDGFSA-N ClC=1C(=CC(=C(CN[C@](C(=O)O)(CO)C)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C=1C(N(C=CC=1)CCCN1C[C@@H](CC1)O)=O)C Chemical compound ClC=1C(=CC(=C(CN[C@](C(=O)O)(CO)C)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C=1C(N(C=CC=1)CCCN1C[C@@H](CC1)O)=O)C DMTZFFWMPMJNHX-KLFBTDGFSA-N 0.000 claims 1
- ZPCKOICHPNUGPA-UMSFTDKQSA-N ClC=1C(=CC(=C(CN[C@](C(=O)O)(CO)C)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C=1C=C2N=CC=NC2=CC=1)C Chemical compound ClC=1C(=CC(=C(CN[C@](C(=O)O)(CO)C)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C=1C=C2N=CC=NC2=CC=1)C ZPCKOICHPNUGPA-UMSFTDKQSA-N 0.000 claims 1
- GJSDHVCPKIREFK-FAIXQHPJSA-N ClC=1C(=CC(=C(CN[C@](C(=O)O)(CO)C)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=NC=CC(=C1C)C1=C(C(=CC=C1)OCCCN1CCCCC1)C Chemical compound ClC=1C(=CC(=C(CN[C@](C(=O)O)(CO)C)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=NC=CC(=C1C)C1=C(C(=CC=C1)OCCCN1CCCCC1)C GJSDHVCPKIREFK-FAIXQHPJSA-N 0.000 claims 1
- KDTXSSLQMGLSCH-MFIBOOTFSA-N ClC=1C(=CC(=C(CN[C@](C(=O)O)(CO)C)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=NC=CC(=C1C)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C Chemical compound ClC=1C(=CC(=C(CN[C@](C(=O)O)(CO)C)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=NC=CC(=C1C)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C KDTXSSLQMGLSCH-MFIBOOTFSA-N 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- CDYCOJVIVOJKGL-MGBGTMOVSA-N N1C=NC2=C1C=CC(=C2)C=1C(=C(COC2=CC(=C(CN[C@@](C(=O)O)(CO)C)C=C2Cl)OCC=2C=NC=C(C=2)C#N)C=CC=1)C Chemical compound N1C=NC2=C1C=CC(=C2)C=1C(=C(COC2=CC(=C(CN[C@@](C(=O)O)(CO)C)C=C2Cl)OCC=2C=NC=C(C=2)C#N)C=CC=1)C CDYCOJVIVOJKGL-MGBGTMOVSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- YWZCINPTVIRQIY-BHVANESWSA-N O1C=CC2=C1C=C(C=C2)C=1C(=C(COC2=CC(=C(CN3[C@@](CCC3)(C(=O)O)C)C=C2Cl)OCC=2C=NC=C(C=2)C#N)C=CC=1)C Chemical compound O1C=CC2=C1C=C(C=C2)C=1C(=C(COC2=CC(=C(CN3[C@@](CCC3)(C(=O)O)C)C=C2Cl)OCC=2C=NC=C(C=2)C#N)C=CC=1)C YWZCINPTVIRQIY-BHVANESWSA-N 0.000 claims 1
- YOJUDIVVBWYGQV-UHFFFAOYSA-N O1C=CC2=C1C=C(C=C2)C=1C(=C(COC2=CC(=C(CNC(C(=O)O)(C)C)C=C2Cl)OCC=2C=NC=C(C=2)C#N)C=CC=1)C Chemical compound O1C=CC2=C1C=C(C=C2)C=1C(=C(COC2=CC(=C(CNC(C(=O)O)(C)C)C=C2Cl)OCC=2C=NC=C(C=2)C#N)C=CC=1)C YOJUDIVVBWYGQV-UHFFFAOYSA-N 0.000 claims 1
- KDQJAOPIRUZOHL-UUWRZZSWSA-N O1C=CC2=C1C=C(C=C2)C=1C(=C(COC2=CC(=C(CN[C@@](C(=O)O)(CO)C)C=C2Cl)OCC=2C=NC=C(C=2)C#N)C=CC=1)C Chemical compound O1C=CC2=C1C=C(C=C2)C=1C(=C(COC2=CC(=C(CN[C@@](C(=O)O)(CO)C)C=C2Cl)OCC=2C=NC=C(C=2)C#N)C=CC=1)C KDQJAOPIRUZOHL-UUWRZZSWSA-N 0.000 claims 1
- MMOBOONTDRNFRG-UHFFFAOYSA-N O1C=CC2=C1C=CC(=C2)C=1C(=C(COC2=CC(=C(CNC(C(=O)O)(C)C)C=C2Cl)OCC=2C=NC=C(C=2)C#N)C=CC=1)C Chemical compound O1C=CC2=C1C=CC(=C2)C=1C(=C(COC2=CC(=C(CNC(C(=O)O)(C)C)C=C2Cl)OCC=2C=NC=C(C=2)C#N)C=CC=1)C MMOBOONTDRNFRG-UHFFFAOYSA-N 0.000 claims 1
- SAOVNFRUGFLWSJ-UUWRZZSWSA-N O1C=CC2=C1C=CC(=C2)C=1C(=C(COC2=CC(=C(CN[C@@](C(=O)O)(CO)C)C=C2Cl)OCC=2C=NC=C(C=2)C#N)C=CC=1)C Chemical compound O1C=CC2=C1C=CC(=C2)C=1C(=C(COC2=CC(=C(CN[C@@](C(=O)O)(CO)C)C=C2Cl)OCC=2C=NC=C(C=2)C#N)C=CC=1)C SAOVNFRUGFLWSJ-UUWRZZSWSA-N 0.000 claims 1
- HDEITTXSTJRYCM-HKBQPEDESA-N O1C=CC2=C1C=CC(=C2)C=1C(=C(COC2=CC(=C(CN[C@H](C(=O)O)CCCNC(=N)N)C=C2Cl)OCC=2C=NC=C(C=2)C#N)C=CC=1)C Chemical compound O1C=CC2=C1C=CC(=C2)C=1C(=C(COC2=CC(=C(CN[C@H](C(=O)O)CCCNC(=N)N)C=C2Cl)OCC=2C=NC=C(C=2)C#N)C=CC=1)C HDEITTXSTJRYCM-HKBQPEDESA-N 0.000 claims 1
- WZYFSKIBWBFGMJ-UHFFFAOYSA-N O1C=NC2=C1C=C(C=C2)C=1C(=C(COC2=CC(=C(CNC(C(=O)O)(C)C)C=C2Cl)OCC=2C=NC=C(C=2)C#N)C=CC=1)C Chemical compound O1C=NC2=C1C=C(C=C2)C=1C(=C(COC2=CC(=C(CNC(C(=O)O)(C)C)C=C2Cl)OCC=2C=NC=C(C=2)C#N)C=CC=1)C WZYFSKIBWBFGMJ-UHFFFAOYSA-N 0.000 claims 1
- KRFBDAAXZASQIA-MGBGTMOVSA-N O1C=NC2=C1C=C(C=C2)C=1C(=C(COC2=CC(=C(CN[C@@](C(=O)O)(CO)C)C=C2Cl)OCC=2C=NC=C(C=2)C#N)C=CC=1)C Chemical compound O1C=NC2=C1C=C(C=C2)C=1C(=C(COC2=CC(=C(CN[C@@](C(=O)O)(CO)C)C=C2Cl)OCC=2C=NC=C(C=2)C#N)C=CC=1)C KRFBDAAXZASQIA-MGBGTMOVSA-N 0.000 claims 1
- YLMGMTGKGVXLPM-HKBQPEDESA-N O1C=NC2=C1C=CC(=C2)C=1C(=C(COC2=CC(=C(CN3[C@@H](CCCC3)C(=O)O)C=C2Cl)OCC=2C=NC=C(C=2)C#N)C=CC=1)C Chemical compound O1C=NC2=C1C=CC(=C2)C=1C(=C(COC2=CC(=C(CN3[C@@H](CCCC3)C(=O)O)C=C2Cl)OCC=2C=NC=C(C=2)C#N)C=CC=1)C YLMGMTGKGVXLPM-HKBQPEDESA-N 0.000 claims 1
- WQLXTWVPXRZATO-MGBGTMOVSA-N O1C=NC2=C1C=CC(=C2)C=1C(=C(COC2=CC(=C(CN[C@@](C(=O)O)(CO)C)C=C2Cl)OCC=2C=NC=C(C=2)C#N)C=CC=1)C Chemical compound O1C=NC2=C1C=CC(=C2)C=1C(=C(COC2=CC(=C(CN[C@@](C(=O)O)(CO)C)C=C2Cl)OCC=2C=NC=C(C=2)C#N)C=CC=1)C WQLXTWVPXRZATO-MGBGTMOVSA-N 0.000 claims 1
- WIAMKRBOMXKTGF-MGBGTMOVSA-N S1C=NC2=C1C=C(C=C2)C=1C(=C(COC2=CC(=C(CN[C@@](C(=O)O)(CO)C)C=C2Cl)OCC=2C=NC=C(C=2)C#N)C=CC=1)C Chemical compound S1C=NC2=C1C=C(C=C2)C=1C(=C(COC2=CC(=C(CN[C@@](C(=O)O)(CO)C)C=C2Cl)OCC=2C=NC=C(C=2)C#N)C=CC=1)C WIAMKRBOMXKTGF-MGBGTMOVSA-N 0.000 claims 1
- YEBXSWDFHVOIOJ-DHUJRADRSA-N S1C=NC2=C1C=CC(=C2)C=1C(=C(COC2=CC(=C(CN3[C@@](CCC3)(C(=O)O)C)C=C2Cl)OCC=2C=NC=C(C=2)C#N)C=CC=1)C Chemical compound S1C=NC2=C1C=CC(=C2)C=1C(=C(COC2=CC(=C(CN3[C@@](CCC3)(C(=O)O)C)C=C2Cl)OCC=2C=NC=C(C=2)C#N)C=CC=1)C YEBXSWDFHVOIOJ-DHUJRADRSA-N 0.000 claims 1
- UYLGAFYWSZQEQI-UHFFFAOYSA-N S1C=NC2=C1C=CC(=C2)C=1C(=C(COC2=CC(=C(CNC(C(=O)O)(C)C)C=C2Cl)OCC=2C=NC=C(C=2)C#N)C=CC=1)C Chemical compound S1C=NC2=C1C=CC(=C2)C=1C(=C(COC2=CC(=C(CNC(C(=O)O)(C)C)C=C2Cl)OCC=2C=NC=C(C=2)C#N)C=CC=1)C UYLGAFYWSZQEQI-UHFFFAOYSA-N 0.000 claims 1
- NAXYKMASDRBSEA-MGBGTMOVSA-N S1C=NC2=C1C=CC(=C2)C=1C(=C(COC2=CC(=C(CN[C@@](C(=O)O)(CO)C)C=C2Cl)OCC=2C=NC=C(C=2)C#N)C=CC=1)C Chemical compound S1C=NC2=C1C=CC(=C2)C=1C(=C(COC2=CC(=C(CN[C@@](C(=O)O)(CO)C)C=C2Cl)OCC=2C=NC=C(C=2)C#N)C=CC=1)C NAXYKMASDRBSEA-MGBGTMOVSA-N 0.000 claims 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000004929 pyrrolidonyl group Chemical group N1(C(CCC1)=O)* 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 0 CCC(C)(CC(C)(C)C(N1CCNCC1)=O)C(C)*(C)C* Chemical compound CCC(C)(CC(C)(C)C(N1CCNCC1)=O)C(C)*(C)C* 0.000 description 5
- HUYXDTFXBCAAFP-UHFFFAOYSA-N CC(C)CCN1CC(C)(C)CC1 Chemical compound CC(C)CCN1CC(C)(C)CC1 HUYXDTFXBCAAFP-UHFFFAOYSA-N 0.000 description 1
- ZNSIKCQCTJHXHF-GQCTYLIASA-N CCC1(C)CN(C/C=C/C)CC1 Chemical compound CCC1(C)CN(C/C=C/C)CC1 ZNSIKCQCTJHXHF-GQCTYLIASA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662359971P | 2016-07-08 | 2016-07-08 | |
| US62/359,971 | 2016-07-08 | ||
| PCT/US2017/040663 WO2018009505A1 (en) | 2016-07-08 | 2017-07-05 | 1,3-dihydroxy-phenyl derivatives useful as immunomodulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019524705A JP2019524705A (ja) | 2019-09-05 |
| JP2019524705A5 true JP2019524705A5 (enExample) | 2020-08-13 |
| JP7168551B2 JP7168551B2 (ja) | 2022-11-09 |
Family
ID=59351131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019500377A Active JP7168551B2 (ja) | 2016-07-08 | 2017-07-05 | 免疫調節剤として有用な１，３－ジヒドロキシフェニル誘導体 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10590105B2 (enExample) |
| EP (1) | EP3481815B1 (enExample) |
| JP (1) | JP7168551B2 (enExample) |
| KR (1) | KR102491992B1 (enExample) |
| CN (1) | CN109689640B (enExample) |
| AU (1) | AU2017292758A1 (enExample) |
| BR (1) | BR112019000247A2 (enExample) |
| CA (1) | CA3029991A1 (enExample) |
| EA (1) | EA201990221A1 (enExample) |
| ES (1) | ES2895066T3 (enExample) |
| IL (1) | IL264092A (enExample) |
| MA (1) | MA45591A (enExample) |
| MX (1) | MX2019000123A (enExample) |
| SG (1) | SG11201900077QA (enExample) |
| WO (1) | WO2018009505A1 (enExample) |
Families Citing this family (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10745382B2 (en) | 2015-10-15 | 2020-08-18 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| KR102401963B1 (ko) | 2016-06-27 | 2022-05-25 | 케모센트릭스, 인크. | 면역조절제 화합물 |
| US10144706B2 (en) | 2016-09-01 | 2018-12-04 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| MA46535A (fr) | 2016-10-14 | 2019-08-21 | Prec Biosciences Inc | Méganucléases modifiées spécifiques de séquences de reconnaissance dans le génome du virus de l'hépatite b |
| KR102599339B1 (ko) * | 2016-12-20 | 2023-11-08 | 브리스톨-마이어스 스큅 컴퍼니 | 면역조정제로서 유용한 화합물 |
| WO2018124766A2 (ko) | 2016-12-28 | 2018-07-05 | 주식회사 녹십자랩셀 | 키메라 항원 수용체 및 이를 발현하는 자연 살해 세포 |
| KR20190133714A (ko) | 2017-03-27 | 2019-12-03 | 브리스톨-마이어스 스큅 컴퍼니 | 면역조정제로서 유용한 치환된 이소퀴놀린 유도체 |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| US11130740B2 (en) | 2017-04-25 | 2021-09-28 | Arbutus Biopharma Corporation | Substituted 2,3-dihydro-1H-indene analogs and methods using same |
| CN111225896B (zh) | 2017-07-28 | 2024-03-26 | 凯莫森特里克斯股份有限公司 | 免疫调节剂化合物 |
| KR102670486B1 (ko) | 2017-08-08 | 2024-05-28 | 케모센트릭스, 인크. | 마크로사이클릭 면역조절제 |
| CA3082328A1 (en) | 2017-11-14 | 2019-05-23 | Green Cross Lab Cell Corporation | Anti-her2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| WO2019123339A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| AU2018392213B2 (en) | 2017-12-20 | 2021-03-04 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
| JP7214752B2 (ja) | 2018-01-23 | 2023-01-30 | ブリストル－マイヤーズ スクイブ カンパニー | 免疫調節剤として有用な２，８－ジアシル－２，８－ジアザスピロ［５．５］ウンデカン化合物 |
| SI3752501T1 (sl) | 2018-02-13 | 2023-08-31 | Gilead Sciences, Inc. | Inhibitorji pd-1/pd-l1 |
| EP3755311A4 (en) | 2018-02-22 | 2021-11-10 | ChemoCentryx, Inc. | INDANAMINE AS PD-L1 ANTAGONISTS |
| JP7050165B2 (ja) | 2018-02-26 | 2022-04-07 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｂｖ複製阻害剤としての置換ピロリジン化合物 |
| US11578054B2 (en) | 2018-03-01 | 2023-02-14 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| EP3774883A1 (en) | 2018-04-05 | 2021-02-17 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
| CA3093130C (en) | 2018-04-19 | 2023-10-17 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| TW202014193A (zh) | 2018-05-03 | 2020-04-16 | 捷克科學院有機化學與生物化學研究所 | 包含碳環核苷酸之2’3’－環二核苷酸 |
| EP3810109B1 (en) | 2018-05-31 | 2024-08-07 | Peloton Therapeutics, Inc. | Compounds and compositions for inhibiting cd73 |
| SI3820572T1 (sl) | 2018-07-13 | 2023-12-29 | Gilead Sciences, Inc. | Inhibitorji pd-1/pd-l1 |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| CN109305934A (zh) * | 2018-08-07 | 2019-02-05 | 成都海博锐药业有限公司 | 苯醚类衍生物及可药用盐、医药上的用途 |
| CN110872275A (zh) * | 2018-08-31 | 2020-03-10 | 深圳微芯生物科技股份有限公司 | 作为免疫调节剂的联苯化合物及其用途 |
| JP7158577B2 (ja) | 2018-10-24 | 2022-10-21 | ギリアード サイエンシーズ， インコーポレイテッド | Ｐｄ－１／ｐｄ－ｌ１阻害剤 |
| TWI721624B (zh) | 2018-10-31 | 2021-03-11 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| CA3117556A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
| SG11202105850YA (en) | 2018-11-02 | 2021-07-29 | Shanghai Maxinovel Pharmaceuticals Co Ltd | Diphenyl-like compound, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and uses thereof |
| CN112876463B (zh) * | 2019-02-21 | 2022-11-11 | 厦门宝太生物科技股份有限公司 | 一种制备pd-l1拮抗剂的中间体及其制备方法 |
| EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| JP7350871B2 (ja) | 2019-03-07 | 2023-09-26 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | ２’３’－環状ジヌクレオチドおよびそのプロドラッグ |
| WO2020178770A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| US20220168268A1 (en) | 2019-03-22 | 2022-06-02 | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. | Small-molecule inhibitor of pd-1/pd-l1, pharmaceutical composition thereof with pd-l1 antibody, and application of same |
| WO2020198672A1 (en) | 2019-03-28 | 2020-10-01 | Bristol-Myers Squibb Company | Methods of treating tumor |
| WO2020198676A1 (en) | 2019-03-28 | 2020-10-01 | Bristol-Myers Squibb Company | Methods of treating tumor |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| CN114340633A (zh) | 2019-05-15 | 2022-04-12 | 凯莫森特里克斯股份有限公司 | 用于治疗pd-l1疾病的三芳基化合物 |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| WO2020243570A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
| CN114127315A (zh) | 2019-05-30 | 2022-03-01 | 百时美施贵宝公司 | 鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法 |
| KR20220016156A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 면역-종양학 요법에의 적합성을 위한 다종양 유전자 시그너쳐 |
| CA3138494A1 (en) * | 2019-06-07 | 2020-12-10 | David Craig Mc Gowan | Heterocyclic immunomodulators as pdl1 checkpoint inhibitor |
| WO2020255021A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and small molecule pdl1 or pd1 inhibitor |
| AU2020294781B2 (en) | 2019-06-20 | 2025-10-09 | Chemocentryx, Inc. | Compounds for treatment of PD-L1 diseases |
| EP3996711A4 (en) | 2019-07-10 | 2023-08-16 | ChemoCentryx, Inc. | Indanes as pd-l1 inhibitors |
| US20220257619A1 (en) | 2019-07-18 | 2022-08-18 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| EP4017476A1 (en) | 2019-08-19 | 2022-06-29 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| CN112457308B (zh) * | 2019-09-09 | 2024-01-02 | 上海长森药业有限公司 | 新型三环芳香杂环化合物，及其制备方法、药物组合物和应用 |
| US20220348653A1 (en) | 2019-09-22 | 2022-11-03 | Bristol-Myers Squibb Company | Quantitative Spatial Profiling for LAG-3 Antagonist Therapy |
| CN112574183B (zh) * | 2019-09-29 | 2022-07-08 | 南京华威医药科技集团有限公司 | 一种pd-1抑制剂及其制备方法和用途 |
| MY208114A (en) | 2019-09-30 | 2025-04-16 | Gilead Sciences Inc | Hbv vaccines and methods treating hbv |
| US11866429B2 (en) | 2019-10-16 | 2024-01-09 | Chemocentryx, Inc. | Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases |
| KR20220084119A (ko) | 2019-10-16 | 2022-06-21 | 케모센트릭스, 인크. | Pd-l1 질환의 치료를 위한 헤테로아릴-바이페닐 아미드 |
| BR112022008191A2 (pt) | 2019-11-08 | 2022-07-12 | Bristol Myers Squibb Co | Terapia com antagonista de lag-3 para melanoma |
| CN116057068A (zh) | 2019-12-06 | 2023-05-02 | 精密生物科学公司 | 对乙型肝炎病毒基因组中的识别序列具有特异性的优化的工程化大范围核酸酶 |
| JP7611591B2 (ja) * | 2019-12-26 | 2025-01-10 | アドレイ・ノーティ・バイオファーマ・カンパニー・リミテッド | Ｐｄ－ｌ１拮抗薬化合物 |
| WO2021188959A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| CN111333629B (zh) * | 2020-04-10 | 2021-03-05 | 颜建发 | 苯基-1h-吡唑类衍生物及其在抗肿瘤药物中的应用 |
| CN115835909A (zh) | 2020-05-05 | 2023-03-21 | 泰昂治疗公司 | 大麻素受体2型（cb2）调节剂和其用途 |
| AU2021331476A1 (en) | 2020-08-28 | 2023-05-04 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hepatocellular carcinoma |
| KR20230061430A (ko) | 2020-08-31 | 2023-05-08 | 브리스톨-마이어스 스큅 컴퍼니 | 세포 국재화 시그너쳐 및 면역요법 |
| WO2022052926A1 (zh) | 2020-09-09 | 2022-03-17 | 广州再极医药科技有限公司 | 芳香乙烯类化合物、其制备方法、中间体、药物组合物及其应用 |
| IL301907A (en) | 2020-10-23 | 2023-06-01 | Bristol Myers Squibb Co | Lag-3 antagonist therapy for lung cancer |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| EP4313127A1 (en) | 2021-03-29 | 2024-02-07 | Juno Therapeutics, Inc. | Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy |
| TW202348237A (zh) | 2021-05-13 | 2023-12-16 | 美商基利科學股份有限公司 | TLR8調節化合物及抗HBV siRNA療法之組合 |
| WO2022261301A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-cancer agents |
| US11931424B2 (en) | 2021-06-11 | 2024-03-19 | Gilead Sciences, Inc. | Combination MCL-1 inhibitors with anti-body drug conjugates |
| AU2022298639C1 (en) | 2021-06-23 | 2025-07-17 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| EP4359389A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7686091B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| CA3222277A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| TW202325306A (zh) | 2021-09-02 | 2023-07-01 | 美商天恩治療有限公司 | 改良免疫細胞之生長及功能的方法 |
| CN118176214A (zh) | 2021-10-29 | 2024-06-11 | 百时美施贵宝公司 | 血液癌症的lag-3拮抗剂疗法 |
| WO2023081730A1 (en) | 2021-11-03 | 2023-05-11 | Teon Therapeutics, Inc. | 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer |
| WO2023097211A1 (en) | 2021-11-24 | 2023-06-01 | The University Of Southern California | Methods for enhancing immune checkpoint inhibitor therapy |
| KR20240135661A (ko) | 2022-01-26 | 2024-09-11 | 브리스톨-마이어스 스큅 컴퍼니 | 간세포성 암종에 대한 조합 요법 |
| EP4487226A1 (en) | 2022-04-08 | 2025-01-08 | Bristol-Myers Squibb Company | Machine learning identification, classification, and quantification of tertiary lymphoid structures |
| EP4554943A1 (en) | 2022-07-14 | 2025-05-21 | Teon Therapeutics, Inc. | Adenosine receptor antagonists and uses thereof |
| CN118265699A (zh) * | 2022-10-26 | 2024-06-28 | 西安新通药物研究股份有限公司 | 一种非对称性联苯衍生物及其制备方法与医药用途 |
| CN120731228A (zh) | 2022-12-21 | 2025-09-30 | 百时美施贵宝公司 | 肺癌的组合疗法 |
| WO2024196952A1 (en) | 2023-03-20 | 2024-09-26 | Bristol-Myers Squibb Company | Tumor subtype assessment for cancer therapy |
| CN116332821B (zh) * | 2023-04-06 | 2025-02-07 | 杭州国瑞生物科技有限公司 | 一种5-(2-氟苯基)-1h-吡咯-3-甲腈的制备方法 |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| US20250345389A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025245489A1 (en) | 2024-05-24 | 2025-11-27 | Bristol-Myers Squibb Company | Treatment of tumors in subjects having fgl-1 positive samples |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6124343A (en) * | 1919-01-27 | 2000-09-26 | Rhone-Poulenc Rorer Limited | Substituted phenyl compounds with a substituent having a thienyl ring |
| US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| TW200815377A (en) * | 2006-04-24 | 2008-04-01 | Astellas Pharma Inc | Oxadiazolidinedione compound |
| EA029901B1 (ru) * | 2013-09-04 | 2018-05-31 | Бристол-Майерс Сквибб Компани | Соединения для применения в качестве иммуномодуляторов |
| US9850225B2 (en) * | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| US10745382B2 (en) * | 2015-10-15 | 2020-08-18 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
-
2017
- 2017-07-05 EP EP17740229.4A patent/EP3481815B1/en active Active
- 2017-07-05 MX MX2019000123A patent/MX2019000123A/es unknown
- 2017-07-05 AU AU2017292758A patent/AU2017292758A1/en not_active Abandoned
- 2017-07-05 WO PCT/US2017/040663 patent/WO2018009505A1/en not_active Ceased
- 2017-07-05 JP JP2019500377A patent/JP7168551B2/ja active Active
- 2017-07-05 US US16/315,800 patent/US10590105B2/en active Active
- 2017-07-05 CA CA3029991A patent/CA3029991A1/en not_active Abandoned
- 2017-07-05 CN CN201780054779.7A patent/CN109689640B/zh active Active
- 2017-07-05 KR KR1020197003664A patent/KR102491992B1/ko active Active
- 2017-07-05 EA EA201990221A patent/EA201990221A1/ru unknown
- 2017-07-05 SG SG11201900077QA patent/SG11201900077QA/en unknown
- 2017-07-05 ES ES17740229T patent/ES2895066T3/es active Active
- 2017-07-05 BR BR112019000247-2A patent/BR112019000247A2/pt not_active Application Discontinuation
- 2017-07-05 MA MA045591A patent/MA45591A/fr unknown
-
2019
- 2019-01-04 IL IL264092A patent/IL264092A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019524705A5 (enExample) | ||
| CN115515947A (zh) | Shp2抑制剂及其组合物和应用 | |
| JP5210866B2 (ja) | キナーゼ阻害剤としての置換ベンゾイミダゾール | |
| JP5384611B2 (ja) | 新規ヘテロ環式化合物およびそれらの使用 | |
| JP2016525076A5 (enExample) | ||
| JP2011503230A5 (enExample) | ||
| JP2015508828A5 (enExample) | ||
| RU2015106784A (ru) | Частично насыщенное азотсодержащее гетероциклическое соединение | |
| RU2008117329A (ru) | Производные имидазопиридина как антагонисты аденозинового рецептора а2в | |
| HRP20220096T1 (hr) | Inhibitori lizin specifične demetilaze-1 | |
| JP2017518961A5 (enExample) | ||
| RU2010137114A (ru) | Амидные производные как позитивные аллостерические модуляторы и способы их применения | |
| RU2020113350A (ru) | Модуляторы белка регулятора трансмембранной проводимости при муковисцидозе и способ применения | |
| RU2009115830A (ru) | Пиридинкарбоксамиды в качестве ингибиторов 11-бета-hsd1 | |
| RU2008141509A (ru) | Mglur5 модуляторы 1 | |
| HRP20120240T1 (hr) | Piridil piperidin antagonisti receptora za oreksin | |
| JP2018535999A5 (enExample) | ||
| NZ609955A (en) | Sgc stimulators | |
| JP2014531465A5 (enExample) | ||
| CA2686378A1 (en) | Pyrimidine derivatives and compositions as c-kit and pdgfr kinase inhibitors | |
| JP2016530299A5 (enExample) | ||
| JP2014527082A5 (enExample) | ||
| IL263511A (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| JP2012528178A5 (enExample) | ||
| SI2981533T1 (en) | Protein Protein Kinase |